Protagonist Therapeutics Inc

NASDAQ:PTGX  
30.96
-0.09 (-0.29%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.47B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$1.74 Million
Adjusted EPS-$0.67
See more estimates
10-Day MA$29.27
50-Day MA$34.70
200-Day MA$33.46
See more pivots

Protagonist Therapeutics Inc Stock, NASDAQ:PTGX

7707 Gateway Boulevard, Suite 140, Newark, California 94560-1160
Phone: +1.510.474.0170
Number of Employees: 79

Description

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.